The new unit, dubbed Fresenius Ventures, will operate over a five-year horizon, focusing on growth areas adjacent to the company’s current strategic pillars: biopharma, MedTech, and care provision. The fund’s mandate includes investments in precision nutrition, microbiome research, and digital care solutions. Beyond capital, the fund offers portfolio companies access to Fresenius’ clinical and scientific networks, alongside regulatory and operational expertise.
In section Releases
Fresenius Launches €200 Million Venture Fund for Health Tech
German healthcare giant Fresenius is launching a dedicated corporate venture capital unit with an investment pool exceeding €200 million. By targeting startups from early-stage to growth, the company aims to secure early access to breakthrough technologies and entrepreneurial talent to bolster its existing pharma and medical platforms.
To lead this expansion, Fresenius has appointed Dr. Thomas Michael Thestrup as Managing Director. Thestrup, who joins from Angelini Ventures, brings 15 years of experience in health tech and research, including previous roles at Lundbeck and UCB. CEO Michael Sen described the initiative as a core component of the company's #FutureFresenius strategy, emphasizing that the fund will serve as a mechanism to integrate external innovations into the existing corporate ecosystem.
Comments (0)
No comments yet. Be the first!